BON vs NEM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The company exhibits weak fundamental health with a Piotroski F-Score of 6/9, indicating borderline stability, and lacks an Altman Z-Score, raising concerns about financial distress risk. Despite trading at a steep discount to the Graham Number ($337.95 vs. current price of $1.70), the business shows deteriorating fundamentals, including a -21.90% YoY revenue decline and minimal profitability. Negative long-term price performance (-99.9% over 5 years) and absence of analyst coverage further signal investor abandonment. While balance sheet metrics appear healthy, the lack of growth, cash flow data, and earnings visibility undermines any value proposition.
NEM shows bullish fundamentals based on deterministic rules. Financial strength is stable (F-Score 4/9). Key strengths include strong valuation and growth metrics. Price trades at a 155.7% premium to fair value estimate ($44.73), limiting near-term upside from a valuation perspective.
Compare Another Pair
Related Comparisons
BON vs NEM: Head-to-Head Comparison
This page compares Bon Natural Life Limited (BON) and Newmont Corporation (NEM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.